- Home
- SITM vs MRNA Comparison
SITM vs MRNA Comparison
Compare SITM & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITM | MRNA |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8B | 21.6B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SITM | MRNA |
|---|---|---|
| Price | $687.03 | $55.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 12 |
| Target Price | ★ $405.00 | $34.27 |
| AVG Volume (30 Days) | 572.9K | ★ 5.0M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.53 | 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | $326,660,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $49.65 | $9.36 |
| Revenue Next Year | $27.77 | $15.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 61.16 | 4.29 |
| 52 Week Low | $186.49 | $22.28 |
| 52 Week High | $901.81 | $59.55 |
Technical Indicators
Market Signals| Indicator | SITM | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 65.04 |
| Support Level | $633.27 | $45.69 |
| Resistance Level | $901.81 | $59.52 |
| Average True Range (ATR) | 48.20 | 3.14 |
| MACD | -4.74 | 0.81 |
| Stochastic Oscillator | 53.62 | 85.10 |
Price Performance
Historical ComparisonAbout SITM SiTime Corporation
SiTime Corp is a provider of Precision Timing solutions to the international electronics industry, providing the timing functionality needed for electronics to operate reliably and correctly. The Company's products are designed to address a wide range of applications across a broad array of end markets. The Company operates a fabless business model and leverages its international network of distributors to address the end markets it serves. The Company operates in one reportable segment related to the design, development, and sale of silicon timing systems solutions. It operates in Hong Kong, Taiwan, the United States, Singapore, and other regions, with the majority of revenue coming from Hong Kong.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.